{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:25:17Z","timestamp":1793913917809,"version":"4.8.0"},"reference-count":138,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T00:00:00Z","timestamp":1641081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death. Although the burden of alcohol- and NASH-related HCC is growing, chronic viral hepatitis (HBV and HCV) remains a major cause of HCC development worldwide. The pathophysiology of viral-related HCC includes liver inflammation, oxidative stress, and deregulation of cell signaling pathways. HBV is particularly oncogenic because, contrary to HCV, integrates in the cell DNA and persists despite virological suppression by nucleotide analogues. Surveillance by six-month ultrasound is recommended in patients with cirrhosis and in \u201chigh-risk\u201d patients with chronic HBV infection. Antiviral therapy reduces the risks of development and recurrence of HCC; however, patients with advanced chronic liver disease remain at risk of HCC despite virological suppression\/cure and should therefore continue surveillance. Multiple scores have been developed in patients with chronic hepatitis B to predict the risk of HCC development and may be used to stratify individual patient\u2019s risk. In patients with HCV-related liver disease who achieve sustained virological response by direct acting antivirals, there is a strong need for markers\/scores to predict long-term risk of HCC. In this review, we discuss the most recent advances regarding viral-related HCC.<\/jats:p>","DOI":"10.3390\/ijms23010500","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T01:15:26Z","timestamp":1641518126000},"page":"500","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-8941","authenticated-orcid":false,"given":"Francesco Paolo","family":"Russo","sequence":"first","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-7178","authenticated-orcid":false,"given":"Alberto","family":"Zanetto","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pinto","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Battistella","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Penzo","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-191X","authenticated-orcid":false,"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Farinati","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,2]]},"reference":[{"key":"ref_1","unstructured":"European Association for the Study of the Liver (2018). Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Burra, P., Zanetto, A., and Germani, G. (2018). Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers, 10.","DOI":"10.3390\/cancers10020046"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_4","unstructured":"European Association for the Study of the Liver (2017). Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and Management of Hepatocellular Carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.28983","article-title":"Hepatocellular carcinoma surveillance: The road ahead","volume":"65","author":"Hernaez","year":"2017","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/liv.14735","article-title":"The changing scenario of hepatocellular carcinoma in Italy: An update","volume":"41","author":"Garuti","year":"2021","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/liv.12208","article-title":"Rise and fall of HCV-related hepatocellular carcinoma in Italy: A long-term survey from the ITA.LI.CA centres","volume":"33","author":"Cazzagon","year":"2013","journal-title":"Liver Int."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zanetto, A., Shalaby, S., Gambato, M., Germani, G., Senzolo, M., Bizzaro, D., Russo, F.P., and Burra, P. (2021). New Indications for Liver Transplantation. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173867"},{"key":"ref_11","first-page":"147","article-title":"Hepatitis B and liver transplantation","volume":"64","author":"Ferrarese","year":"2018","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jhep.2016.09.013","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection","volume":"66","author":"Chayanupatkul","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.4254\/wjh.v7.i13.1742","article-title":"Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma","volume":"7","author":"Baran","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/jac\/dku041","article-title":"Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B","volume":"69","author":"Hsu","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","article-title":"Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: A systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jvh.12832","article-title":"Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir","volume":"25","author":"Hsu","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3748\/wjg.v22.i4.1570","article-title":"Liver transplantation for viral hepatitis in 2015","volume":"22","author":"Ferrarese","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_21","unstructured":"Polaris Observatory HCVC (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies","volume":"158.5 Pt. 1","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bpg.2014.07.017","article-title":"Role of antiviral treatment for HCC prevention","volume":"28","author":"Colombo","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19698","DOI":"10.3390\/ijms160819698","article-title":"Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy","volume":"16","author":"Colombo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.29855","article-title":"Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout","volume":"68","author":"Huang","year":"2018","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ajg.2014.214","article-title":"Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans","volume":"109","author":"Kramer","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"key":"ref_30","unstructured":"European Association for the Study of the Liver (2018). Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on hepatitis E virus infection. J. Hepatol., 68, 1256\u20131271."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Klohn, M., Schrader, J.A., Bruggemann, Y., Todt, D., and Steinmann, E. (2021). Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13225867"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., and Omata, M. (2019). Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061358"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/nsr\/nwu038","article-title":"The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma","volume":"1","author":"Yang","year":"2014","journal-title":"Natl. Sci. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep4.1781","article-title":"More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC","volume":"5","author":"Zanetto","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zanetto, A., Senzolo, M., Campello, E., Bulato, C., Gavasso, S., Shalaby, S., Gambato, M., Vitale, A., Cillo, U., and Farinati, F. (2021). Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers, 13.","DOI":"10.3390\/cancers13051150"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jvh.13551","article-title":"Hepatitis B virus-induced hepatocarcinogenesis: A virological and oncological perspective","volume":"28","author":"Arslan","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2009.10.033","article-title":"Mechanisms of HBV-related hepatocarcinogenesis","volume":"52","author":"Neuveut","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.3748\/wjg.v20.i33.11630","article-title":"Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis","volume":"20","author":"Tarocchi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Torresi, J., Tran, B.M., Christiansen, D., Earnest-Silveira, L., Schwab, R.H.M., and Vincan, E. (2019). HBV-related hepatocarcinogenesis: The role of signalling pathways and innovative ex vivo research models. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5916-6"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wang, S.H., Yeh, S.H., and Chen, P.J. (2021). Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers, 13.","DOI":"10.3390\/cancers13102454"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, D., Guo, S., and Schrodi, S.J. (2021). Mechanisms of DNA Methylation in Virus-Host Interaction in Hepatitis B Infection: Pathogenesis and Oncogenetic Properties. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189858"},{"key":"ref_43","first-page":"20","article-title":"Earliest hepatitis B virus-hepatocyte genome integration: Sites, mechanism, and significance in carcinogenesis","volume":"7","author":"Chauhan","year":"2021","journal-title":"Hepatoma Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tu, T., Budzinska, M.A., Shackel, N.A., and Urban, S. (2017). HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 9.","DOI":"10.3390\/v9040075"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1073\/pnas.83.8.2531","article-title":"Common evolutionary origin of hepatitis B virus and retroviruses","volume":"83","author":"Miller","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s005350170027","article-title":"Hepatitis B virus X protein: A multifunctional viral regulator","volume":"36","author":"Murakami","year":"2001","journal-title":"J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/sj.onc.1204495","article-title":"Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis","volume":"20","author":"Huo","year":"2001","journal-title":"Oncogene"},{"key":"ref_49","first-page":"6012","article-title":"Abrogation of p53-induced apoptosis by the hepatitis B virus X gene","volume":"55","author":"Wang","year":"1995","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1074\/jbc.273.1.381","article-title":"X-gene product of hepatitis B virus induces apoptosis in liver cells","volume":"273","author":"Kim","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lab.2004.11.018","article-title":"Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells","volume":"145","author":"Zhang","year":"2005","journal-title":"J. Lab. Clin. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2010.12.010","article-title":"Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad","volume":"21","author":"Monga","year":"2011","journal-title":"Semin. Cancer Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Phesse, T., Flanagan, D., and Vincan, E. (2016). Frizzled7: A Promising Achilles\u2019 Heel for Targeting the Wnt Receptor Complex to Treat Cancer. Cancers, 8.","DOI":"10.3390\/cancers8050050"},{"key":"ref_54","first-page":"5389","article-title":"Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice","volume":"61","author":"Deane","year":"2001","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23099","article-title":"S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis","volume":"50","author":"Nemeth","year":"2009","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1074\/jbc.R100063200","article-title":"Signaling networks that link cell proliferation and cell fate","volume":"277","author":"Sears","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1073\/pnas.1502400112","article-title":"Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33525","DOI":"10.1074\/jbc.M506628200","article-title":"The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage","volume":"280","author":"Lee","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.21445","article-title":"Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice","volume":"45","author":"Zheng","year":"2007","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/sj.onc.1210279","article-title":"TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer","volume":"26","author":"Hussain","year":"2007","journal-title":"Oncogene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1099\/vir.0.007211-0","article-title":"Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells","volume":"90 Pt 5","author":"Liao","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrgastro.2012.114","article-title":"Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma","volume":"9","author":"Majumdar","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9044","DOI":"10.1128\/JVI.00130-12","article-title":"Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission","volume":"86","author":"Shih","year":"2012","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22654","article-title":"Hepatitis delta virus inhibits alpha interferon signaling","volume":"49","author":"Pugnale","year":"2009","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JHC.S221187","article-title":"Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment","volume":"7","author":"Dash","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1096\/fj.06-7345com","article-title":"Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity","volume":"21","author":"Li","year":"2007","journal-title":"FASEB J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3748\/wjg.v22.i4.1461","article-title":"Metabolic alterations and hepatitis C: From bench to bedside","volume":"22","author":"Chang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.bbalip.2018.06.002","article-title":"Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication","volume":"1863","author":"Hofmann","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1189\/jlb.0207128","article-title":"Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins","volume":"82","author":"Chang","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10620-010-1395-y","article-title":"HCV-related proteins activate Kupffer cells isolated from human liver tissues","volume":"56","author":"Hosomura","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"ref_74","unstructured":"Pelizzaro, F., Peserico, G., D\u2019Elia, M., Cazzagon, N., Russo, F.P., Vitale, A., Giannini, E.G., Piccinnu, M., Rapaccini, G.L., and Di Marco, M. Surveillance for hepatocellular carcinoma with a 3-months interval in \u201cextremely high-risk\u201d patients does not further improve survival. Dig. Liver Dis., 2021, in press."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1136\/gutjnl-2015-310818","article-title":"Real-world risk score for hepatocellular carcinoma (RWS-HCC): A clinically practical risk predictor for HCC in chronic hepatitis B","volume":"65","author":"Poh","year":"2016","journal-title":"Gut"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiz477","article-title":"Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy","volume":"221","author":"Yang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.28702","article-title":"Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)","volume":"64","author":"Layese","year":"2016","journal-title":"Hepatology"},{"key":"ref_84","first-page":"2205","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study","volume":"19","author":"Tani","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4254\/wjh.v7.i5.777","article-title":"Hepatitis D and hepatocellular carcinoma","volume":"7","author":"Abbas","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1038\/s41598-021-87679-w","article-title":"Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide\/nucleoside analogues","volume":"11","author":"Jang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/gutjnl-2020-321627","article-title":"Prioritisation and the initiation of HCC surveillance in CHB patients: Lessons to learn from the COVID-19 crisis","volume":"69","author":"Zeng","year":"2020","journal-title":"Gut"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cld.2021.06.011","article-title":"New Treatments for Chronic Hepatitis B Virus\/Hepatitis D Virus Infection","volume":"25","author":"Sandmann","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir","volume":"25","author":"Kim","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/apt.13034","article-title":"Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: A prospective-retrospective study","volume":"41","author":"Chong","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2036.2011.04634.x","article-title":"Meta-analysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma","volume":"33","author":"Wong","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2009.08.003","article-title":"Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence","volume":"51","author":"Hoshida","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/hep.31590","article-title":"Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection","volume":"73","author":"Yuan","year":"2021","journal-title":"Hepatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s10620-019-05543-4","article-title":"Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma","volume":"64","author":"Jian","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jvir.2011.11.012","article-title":"Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: Improved survival after concomitant treatment with nucleoside analogues","volume":"23","author":"Toyoda","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40880-015-0017-7","article-title":"Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization","volume":"34","author":"Zhou","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","article-title":"Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study","volume":"58","author":"Ogawa","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","article-title":"AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"Kanwal","year":"2016","journal-title":"Hepatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","article-title":"Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada","volume":"66","author":"Janjua","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/liv.13873","article-title":"Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals","volume":"38","author":"Russo","year":"2018","journal-title":"Liver Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/jvh.13215","article-title":"Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance","volume":"27","author":"Russo","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.3748\/wjg.v24.i38.4403","article-title":"Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study","volume":"24","author":"Ferrarese","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jvh.12746","article-title":"Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents","volume":"24","author":"Schiavinato","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pinero","year":"2019","journal-title":"Liver Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/lt.24790","article-title":"Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals","volume":"23","author":"Zanetto","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Sapena, V., Enea, M., Torres, F., Celsa, C., Rios, J., Rizzo, G.E.M., Nahon, P., Marino, Z., Tateishi, R., and Minami, T. (2021). Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis. Gut.","DOI":"10.1136\/gutjnl-2020-323663"},{"key":"ref_126","first-page":"10","article-title":"A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure","volume":"ACG","author":"Ampuero","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.3748\/wjg.v27.i40.6737","article-title":"Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?","volume":"27","author":"Ahumada","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Semmler, G., Meyer, E.L., Kozbial, K., Schwabl, P., Hametner-Schreil, S., Zanetto, A., Bauer, D., Chromy, D., Simbrunner, B., and Scheiner, B. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J. Hepatol., 2021, in press.","DOI":"10.1016\/j.jhep.2021.11.025"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.31462","article-title":"Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease","volume":"73","author":"Semmler","year":"2021","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"Rimassa","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.23736\/S2724-5985.20.02775-0","article-title":"Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma","volume":"67","author":"Ferrarese","year":"2021","journal-title":"Minerva Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11864-021-00886-5","article-title":"Immunotherapy in Hepatocellular Carcinoma","volume":"22","author":"Fulgenzi","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"108128","DOI":"10.1016\/j.intimp.2021.108128","article-title":"Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma","volume":"100","author":"Liu","year":"2021","journal-title":"Int. Immunopharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:59:56Z","timestamp":1760363996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,2]]},"references-count":138,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23010500"],"URL":"https:\/\/doi.org\/10.3390\/ijms23010500","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,2]]}}}